San Diego, CA (PRWEB) January 14, 2014
Histogen, Inc., a regenerative medicine company developing solutions based on the products of cells grown under simulated embryonic conditions, today announced that they have entered into an international license agreement with Suneva Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent cell conditioned media (CCM).
This agreement is an amendment to the existing license between Histogen and Suneva Medical, through which Suneva has exclusively licensed the Regenica® skincare line within the United States since February 2012. Under the terms of the international agreement, Suneva Medical is now the exclusive licensee for the distribution of Regenica through the physician-dispensed channel in Europe, most of Asia, South America, Canada, Australia, and the Middle East.
“Not only has Suneva had sales success, but they have generated enthusiasm around the Regenica product line and our technology here in the US,” said Gail K. Naughton, Ph.D., CEO and Chairman of the Board of Histogen. “We are excited about expanding our skincare partnership internationally, and look forward to an exciting year for Regenica.”
Regenica contains Histogen’s proprietary Multipotent Cell Conditioned Media, made up of soluble cell-signaing proteins and growth factors which support the body’s epidermal stem cells and renew skin throughout life. Through Histogen’s technology process, which mimics the embryonic environment including conditions of low oxygen and suspension, cells are triggered to become multipotent, and naturally produce these proteins associated with skin renewal and scarless healing.
“We believe that Regenica truly is the next generation in growth factor technology, and we are extremely pleased that the products will now have a presence around the world,” said Nicholas L. Teti, Jr., Chairman and Chief Executive Offic
Copyright©2012 Vocus, Inc.
All rights reserved